Form 4: Insider Transactions at Shoulder Innovations

Director and 10% owner Geoffrey B. Pardo reported significant common stock acquisitions and preferred stock conversions related to Shoulder Innovations, Inc.'s IPO.

Summary

• Geoffrey B. Pardo, a Director and 10% owner of Shoulder Innovations, Inc., reported several transactions with an effective date of August 1, 2025.
• Preferred stock (Series D and Series E) held indirectly by Cooperatieve Gilde Healthcare V U.A. (Gilde), where Mr. Pardo is a partner, automatically converted into common stock immediately prior to the Issuer's initial public offering (IPO).
• Specifically, 33,259,424 shares of Series D Preferred Stock converted into 1,743,156 shares of Common Stock, and 10,252,188 shares of Series E Preferred Stock converted into 537,326 shares of Common Stock.
• An additional 2,280,482 shares of Common Stock were acquired indirectly through a conversion (Transaction Code C).
• Gilde also purchased 100,000 shares of Common Stock at a price of $15 per share.
• Mr. Pardo received a direct award of 7,666 restricted stock units (RSUs) with a price of $0.
• The RSUs will vest on the earlier of the 2026 annual meeting of stockholders or August 1, 2026.
• Following these reported transactions, the indirect beneficial ownership through Gilde is 2,380,482 shares of Common Stock, and direct beneficial ownership is 7,666 shares of Common Stock.

Sentiment

Score: 7

Explanation: The filing indicates a significant insider's commitment through stock purchases and RSU awards, alongside the company's recent IPO, which are generally positive indicators. The transactions are routine for an IPO and insider disclosures, reflecting standard corporate finance activities.

Positives

• Significant insider ownership by a Director and 10% owner aligns interests with shareholders.
• The purchase of 100,000 shares at $15 by an affiliated entity (Gilde) indicates confidence in the company's valuation by a significant shareholder/director.
• The RSU award to Mr. Pardo provides long-term incentive and aligns his interests with future company performance.

Future Outlook

The vesting schedule for the restricted stock units indicates a future milestone for Mr. Pardo's compensation, with vesting expected by August 1, 2026, or the 2026 annual meeting.

Management Comments

• Mr. Pardo disclaims beneficial ownership of shares held by Gilde, except to the extent of his pecuniary interest in the shares.

Industry Context

The transactions, particularly the preferred stock conversion tied to an initial public offering (IPO), suggest a significant corporate event for Shoulder Innovations, Inc., indicating its transition to a publicly traded entity. This aligns with broader trends of private companies seeking public capital for growth and expansion, especially within the medical device sector.

Comparison to Industry Standards

• The conversion of preferred stock into common stock prior to an IPO is a standard practice for venture-backed companies going public, ensuring a simplified capital structure for public trading.
• The purchase of shares by a director/10% owner at the IPO price is a common show of confidence, comparable to similar insider purchases seen in other medical device or healthcare IPOs.
• The RSU award is a typical form of long-term incentive compensation for executives and directors in newly public companies, aligning their interests with shareholder value creation.

Related Party Transactions

• Shares held indirectly by Cooperatieve Gilde Healthcare V U.A. (Gilde), where reporting person Geoff Pardo is a partner, indicating a related party relationship for the indirect holdings and transactions.

Stakeholder Impact

• Shareholders: Increased transparency regarding insider holdings and transactions. The purchase of shares by a director/10% owner at $15 per share may signal confidence to other investors.
• Employees: The RSU award to a director aligns executive incentives with long-term company performance, potentially benefiting all stakeholders through improved governance and strategic focus.

Next Steps

• Vesting of 7,666 restricted stock units on the earlier of the 2026 annual meeting of stockholders or August 1, 2026.

Key Dates

Recommendation

This Form 4 primarily discloses routine insider transactions following an IPO, including preferred stock conversions and an RSU award, along with a purchase by an affiliated entity. While the purchase at $15 indicates insider confidence, the filing itself does not provide new fundamental financial data or strategic shifts that would warrant a 'buy' or 'sell' recommendation. It confirms the capital structure post-IPO and insider alignment, suggesting a 'hold' as investors assess the company's ongoing performance.

Keywords

SHOULDER INNOVATIONS, SI, Form 4, Insider Trading, Beneficial Ownership, Stock Conversion, Restricted Stock Units, IPO, Gilde Healthcare, Director, 10% Owner